Open access peer-reviewed chapter

Signaling Pathway for the Development of Pre-B Cells

By Tatsuaki Tsuruyama

Submitted: February 28th 2018Reviewed: June 23rd 2018Published: November 5th 2018

DOI: 10.5772/intechopen.79733

Downloaded: 837


Pre-B cells represent the immature stage of the B cell lineage and express genes for the pre-B cell receptor (preBCR). PreBCR consists of lambda 5 and VpreB and its expression elicits a rearrangement of the immunoglobulin heavy chain prior to rearrangement of the immunoglobulin light chain. The lambda 5 and VpreB form a surrogate light chain, which is a premature type of light chain immunoglobulin. PreBCR may cooperate or interact with the IL-7 receptor, which contributes to pre-B cell development. The preBCR distal signaling pathway recruits several adaptor proteins and protein kinases. This review aims to illustrate the framework of the signaling pathway that contributes to B cell lineage development and reconsiders the relationship between the preBCR and IL-7 receptors.


  • pre-B cell receptor
  • IL-7 receptor
  • ZFP521
  • adaptor protein
  • rearrangement of immunoglobulin

1. Introduction

B cell lymphocytes develop from common lymphocyte progenitors (CLPs) to form mature B cells, plasma cells, or memory B cells in close association with immunoglobulin genes (Ig)rearrangement. Igrearrangement (IgR) status is a phenotypic marker of immature B cell lineage. IgR occurs with the stepwise rearrangement of the V, D, and J segments of the immunoglobulin heavy chain (IgH) and immunoglobulin light chain (IgL) gene chain in the bone marrow. PreBCR is transiently expressed by developing precursor B cells.

The surrogate light chain is tentatively expressed on the membrane surface, followed by expression of mature IgL. Surrogate light and heavy chains form preBCR, involving the adaptor proteins CD79a and CD79b (alternatively termed as Igαand Igβ). It is not clear how preBCR reacts with external derived antigens and contributes to the formation of mature B cell receptors (BCR). To understand the role of preBCR, it is necessary to elucidate the preBCR distal signaling pathway. It is well known that many key kinases participate in the BCR signaling pathway, such as spleen tyrosine kinase (Syk), bruton’s tyrosine kinase (Btk), B lymphocyte kinase (Blk), and a transcriptional repressor Blimp (B lymphocyte-induced maturation protein). BP-1 (CD249) is another key player in the immature B cell lineage. In this article, the preBCR signaling pathway will be reviewed in reference to the BCR pathway in mice.

The B cell developmental stage has been extensively investigated using surface markers for the appropriate preBCR antibodies. The best known classification for immature phenotype markers is the Hardy’s classification fraction (Fr) [1]. These markers range from Fr. A–D (Fr. A: B220+, IgM-, BP-1-, CD43+, and CD24-; Fr. B: B220+, IgM-, BP-1-, CD43+, and CD24+; Fr. C: B220+, IgM-, BP-1+, CD43+, and CD24+; Fr. C′: B220+, IgM-, BP-1+, CD43+, and CD24high; and Fr. D: B220+, IgM-, BP-1-, CD43-, and CD24+) with ongoing IgHrecombination [2, 3, 4].


2. Signal cascade in pre-B cells

2.1. IL-7 and IL-7R signaling cascade

IL-7 and IL-7R play crucial roles in B cell development that function in parallel with Igrecombination. IL-7R is a heterodimer of the α chain (CD 127) and the common γ chain (γc chain). IL-7Rα chains are primarily expressed in thymocytes, dendritic cells, mature T cells, and monocytes. This molecule is also expressed on the surface of pre-B cell lineages, but not on mature B cell lineages. In T cells and pre-B cells, the signal cascade via IL-7R recruits Janus kinases (JAKs), activates the signal transducer and activator of transcription (Stat) by phosphorylation. Among JAKs, Jak2 lacks Src homology binding domains (SH2/SH3) and JAK homology domains (JH1-JH7). The carboxy-terminal JH domain contains full kinase function (JH1), while the JH2 domain has significantly lower kinase activity than the JH1 domain. JAKs are recruited when IL-7 binds to IL-7R, leading to IL-7R auto-phosphorylation. Phosphorylated tyrosine residues of JAKs bind Stats with an SH2 domain [5] and Stat is phosphorylated by JAK. Phosphorylated STAT forms a dimer and translocate to the nucleus. Thereafter, the dimeric STAT binds to the promoter region containing palindromic gamma interferon activation site (GAS) elements that are positioned upstream of Bcl-xL, Cyclin D1, pim1, c-myc, and other genes inducing proliferation [6]. Suppressor of cytokine signaling (SOCS) controls this cascade in a feedback manner, because the Socsgene promoter has the GAS element. The SOCS family negatively controls by binding to JAKs. For example, the SOCS3 protein can bind to JAK2 kinase and inhibit its activity [7].

JAK2mutations have been implicated in myeloid proliferative disorders such as chronic myeloid leukemia [8] polycythemia vera [9], primary myelofibrosis, essential thrombocythemia, and pre-B or lymphoblastic mature B ALL [10]. In these disorders, a change of valine to phenylalanine at the 617 position (V617F) in JAK2 induces higher sensitivity to cytokines such as erythropoietin, thrombopoietin, and IL-7. In therapies targeting JAK2-STAT5 inhibition, JAK2mutations are observed in the poor prognostic BCR-ABL1-like subtypes of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Momelotinib and ruxolitinib were therapeutically effective for ALL. In the development of the lymphoblastic cells, the JAK-STAT pathway plays an important role [10].

IL-7R expression is also controlled in a developmental stage dependent manner. In parallel with Igheavy chain rearrangement in pre-B cells (termed large pre-B or pre-B I), IL-7R expression augments and gradually decreases with expression of the surrogate light chain, consisting of VpreB and lambda5. Accordingly, the enhanced effect of the IL-7R signaling cascade is limited to the large pre-B or pre-B I stage. Accordingly, the pre-B ALL phenotype may depend on the IL-7R pathway. Thus, the activated pathway may determine the tumor phenotype. In the bone marrow, stromal cells actively produce IL-7 and promote the proliferation of bone marrow pre-B cells. Cytokine dependency is also observed in T cell leukemia/lymphoma and Human T-cell Leukemia/lymphoma Type 1 (HTLV-I)-induced adult T cell leukemia/lymphoma. When the pre-B cells develop immature-B cells, such dependency on the IL-7 and IL-7R pathway is lost and immature-B cells are recruited to extra-bone marrow area. In contrast, the excess IL-7R expression on the tumor progenitor cells may be activated by lower IL-7 in the peripheral environment, which may result in tumor development. However, the effect of IL-7 on human and mouse pre-B cells are different for proliferation and there have been reports that IL-7 may not be an essential factor in human cells.

Further, the relationship between IL-7R and Jak-STAT during Igrearrangement remains controversial. In a previous study, MLV-integration based Stat5 activation was observed in pre-B cell lymphomas in an inbred strain of SL/Kh mice [9]. However, the dependency of proliferation on IL-7R is a part of lymphomagenesis, because the genetic background or microsatellite instability unique to this strain is also required [18]. For this reason, Stat5 activation is not sufficient for pre-B cell lymphoma or ALL [6].

2.2. IL-7R signaling cascade and Ig rearrangement

There has been discussion regarding the relationship between IL-7R signal cascades RAG1/2 (recombination activating gene 1/2) that mediate Igrearrangement. In fact, it is not clear how transcription factors mediate transcriptional repression of Rag. Recombination activating implies that this gene is involved in immunoglobulin V-D-J recombination. The cleavage activity of RAG1 requires RAG2 as a partner. The RAG-1/2 complex nicks the Recombination Signal Sequence (RSS) that flanks the V, D, and J regions.

In the RAG1/RAG2 complex, RAG1 has the most catalytic activity while RAG2 provides a binding scaffold for the tight association with DNA [11]. There has been a controversial discussion in previous reports that the IL-7R pathway may enhance or suppress recombination. To explain the opposing effect of IL-7, it acts on Igrearrangement in a dose-dependent manner. RSSs consists of three elements, heptamer sequences, spacer sequences, and nonamer sequences that flanks the V, D, and J sequences in the IgHand the V and J sequences in the IgLregion. Spacer sequences are either 12 base pairs or 23 base pairs long and are located between the heptamer and nonamer sequences. Heptamer sequences are CACAGTG and nonamers are usually ACAAAAACC. After rearrangement, RSSs are spliced out of the final IgmRNA. When B cells undergo IgHrearrangement, IL-7R expression increases, suggesting that IL-7R may be associated with the rearrangement. However, the downstream molecule Stat5 may contribute to suppression of the rearrangement. As a candidate for the suppression effect, Ebf1 expression is promoted by Stat5, suggesting a link between the negative regulations of Rag transcription [12]. Using model mice with Stat5 high expression, the IgHrearrangement was repressed. A schematic representation of immunoglobulin loci is illustrated below (Figures 1 and 2).

Figure 1.

A scheme of B cell differentiation and immunoglobulin rearrangement.

Figure 2.

Immunoglobulin gene loci. VH, variable segment; D, diverse segment, J, junction segment. Vk, variable segment of kappa light chain.

2.3. PreBCR and surrogate light chain

PreBCR is expressed on a large pre-B cell after or during IgHrearrangement. This contains a surrogate light chain consisting of VpreB and lambda 5. In addition, CD79a, CD79b, and the Ig muH chain participate in the formation of preBCR. Although it is not clear how antigens or ligands stimulate preBCR, signaling through preBCR controls allelic exclusion. One of the IgHlocus rearrangements is inactive, promotes proliferation, and induces differentiation to small pre-B cells. IgLrearrangement follows this expression of preBCR. IgLrearrangement proceeds after the expression of preBCR in small pre-B cells. CD79a and CD79b contain tyrosine-rich ITAMs that can recruit the cytosolic SRC homology 2 (SH2)-domain-containing SYK following phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs). One of the pan-B cell markers, CD19 and CD45, interact with the preBCR to serve as regulators of positive signaling. In contrast, negative signaling and the regulatory mechanisms of preBCR have not been sufficiently addressed, Therefore, preBCR signaling has not been elucidated. It is possible that immunoreceptor tyrosine-based inhibitory motifs (ITIMs) function to recruit cytosolic protein tyrosine phosphatases (PTPs) such as SH2-domain-containing PTP 1 (SHP1). PIK3K is another adaptor protein of the CD79a and CD79b heterodimer. The RAS-ERK cascade and AKT-FOXO cascade may induce a positive signal inducing proliferation and BCl6, a marker of diffuse large B cell lymphoma/leukemia that may induce B cell lineage proliferation.

SYK can associate with other protein kinases, LYN and Slp65 /BLK or BLNK, that recruit BTK in a phosphorylation dependent manner. BTK associates with SLP-65, also known as BLNK or BASH, another important linker protein. BLNK suppresses Pre-B cell leukemogenesis through JAK3 inhibition [13, 14, 15]. BLNK KO mice developed pre-B cells or ALL in an experimental study. BLNK is part of a signaling complex involving Grb-2 and Vav, prior to arrangement of the cytoskeleton. BLNK, BTK, and PLCgamma 2 may form a complex that promotes IRF4 expression linked to IgLrearrangement that suppresses or downregulates the preBCR and IL-7R signal cascades simultaneously. In this way, the transition of IgHrearrangement to IgLrearrangement is controlled by the orchestration of various kinases and adaptor proteins. BLNK is involved in switching cell fate from proliferation to differentiation [16]. Additionally, BLNK recruits active H-Ras to the BCR complex, which is essential for sustained BCR surface expression and for the signal leading to functional ERK activation [17], potentially resulting in B-cell proliferation. Upregulation of BLNKmay be a consequence of the negative-feedback mechanism and this upregulation results in tumor suppression. BLNK knockdown resulted in downregulation of BP-1, a pre-B cell marker [18]. Mice deficient in Slp65 /Blnk spontaneously develop pre-B cell leukemia [13], originating from pro-B cells with V(H)-to D-J(H) recombination. Nevertheless, IgHrearrangement was restricted to V(H)14-1 and V(H)14-2, V(H)14 IgHchains did not provide increased proliferative signals. PreBCR specificity did not contribute to oncogenic transformation.

Ikaros is required for the differentiation of large pre-B to small pre-B cells and is also required for the down-regulation of the preBCR, Igκ germline transcription, and IgLchain recombination. The Ikaros family are regulators of B-cell development by DNA-binding. Ikaros functions as a tumor suppressor in pre-B ALL [19] by controlling BCR-ABL1 kinase signaling from SRC kinase-activation to BLNK [20] or c-Myc expression [21]. Interestingly, BCR-ABL1 induces aberrant splicing of Ikaros in pre-B ALL [22]. The loss of Ikaros DNA-binding function leads to the progression of acute lymphoblastic leukemia [23]. Recently, MLL1 is found to be a regulator of preBCR signaling [24].

2.4. Orchestration of the preBCR and IL-7R signal cascades

In developing B cells, the IL-7R and preBCR synergize or act exclusively to induce proliferation [25]. However, preBCR is also critical to control differentiation through suppression of c-Myc function in large preB cells [26]. PreBCR is thus timely expressed in the transition of large to small preB cells [27]. PreBCR signaling does not affect interactions between the intronic enhancer and V (kappa) genes in proB cells. The kappa enhancers interact with the V (kappa) region already in proB cells. PreBCR signaling induces accessibility through functional redistribution of long-range chromatin interactions within the V(kappa) region [28]. ZFP521expression during cell growth is attenuated by the addition of IL-7 [16, 29]. Stimulation of preBCR modulated the growth of ZFP521-overexpressing cells [25]. IL-7 and preBCR control the development of preB cells into mature B cells [27, 30]. When IL-7R expression is gradually attenuated during the late stage of large preB cell development, preBCR signaling replaces the dominant pathway. B-cell development is controlled in a stepwise manner where the first stage of development is completed before the subsequent stages are initiated.

There has been discussion as to whether preBCR functions as a tumor suppressor in the all cases of human acute lymphoblastic leukemia lymphoma (ALL). A distinct subset of human ALL is sensitive to preBCR [31]. The effects of preBCR stimulation were attenuated by the addition of IL-7 [16, 29]. Although both pathways are orchestrated during B-cell development [27], they are linked with immunoglobulin rearrangement [32]. During the development of pro-B cells into pre-B cells, IL-7 signaling is a major mediator with IL-7R expressed at high levels. In contrast, during the development of pre-B cells into mature B cells, preBCR signaling may be the dominant pathway after IL-7R expression is attenuated. Thereafter, mature BCR replaces preBCR. B-cell development is controlled in a stepwise manner in which the first stage of development is completed before the subsequent stages are initiated. In summary, the relationship between preBCR and the IL-7R cascade is complicated and forms an interactive network. The outcome of pre-B cell stimulation is difficult to predict in terms of proliferation or development. This network may be a necessary checkpoint for the developmental stage in a dose-dependent of IL-7 and other stimuli (Figure 3).

Figure 3.

The interactive responsiveness to stimulation through preBCR, IL-7, and other signaling cascades. In this scheme, bank 1 is selected for the modulator that is controlled by zfp521.

2.5. Other candidate cascades in pre-B cells

We previously reported that MLV insertion into the signal transducer and activator of transcription factor 5 (Stat5), Homeodomain-interacting protein kinase 2 (Hipk2), and Flt3-interacting zinc finger protein 1 (Fiz1) in the pre-B cell lymphoma genome. These genes encode proteins that are involved in pre-B cell-specific molecular signaling pathways such as IL-7R, CD43, and Fms-like tyrosine kinase 3 (FLT3). The dysregulation of this preBCR signal is responsible for pre-B cell lymphomagenesis [33]. ZFP521 contributed to mouse and human pre-B-cell lymphomagenesis (i.e., human B-cell lymphoblastic lymphoma). Pre-B cell proliferation depended on the activation of preBCR signaling molecules, which were upregulated by ZFP521.

2.6. Pre-B cell and acute lymphoblastic neoplasia in mouse

To date, pre-B cell lines from acute lymphoid tumors require strict cell culture conditions and consistent time course research. Using these cell line, IL-7 supply is critical, but IL-7 and v-Ha-ras expression are not individually sufficient to induce tumorigenicity. Their co-expression yields highly tumorigenic pre-B lymphoid cell lines [34].

On the other hand, as an experimental model, SL/Kh is known to be useful for tumorigenesis of pre-B cells and signaling pathways. This strain has two copies of AKV endogenous MLV and other retrovirus-derived fragments [3]. The expressed viral vector infects the host B cell progenitors and retroviral elements, such as promoters and enhancers promote Stat5, c-myc, ZFP521, N-myc, and other oncogenes [3, 6, 18, 35, 36, 37]. For this, this strain serves as an appropriate model for analysis of interaction between these molecules and their related signal pathways.

2.7. Role of ZFP521during lymphoid differentiation

The mechanisms by which preBCR-related genes are controlled are not sufficiently understood relative to the mature B cell receptor. ZFP521has been recently recognized as an important gene in pre-B cell lymphomagenesis. When ZFP521is upregulated, BTK, BLNK, and BANK1 are involved in the preBCR signaling pathway and are comprehensively upregulated. ZFP521 contributes to the upregulation of Ccnd3and Ccnd2,enhancing the cell cycle and inducing proliferation. In a previous study, preBCR also activates the Ras-MEK-extracellular signal-regulated kinase (ERK) pathway, cell cycle exit, and light chain recombination by silencing Ccnd3[38]. Ccnd3gene expression is probably responsible for the growth of pre-B cells [39]. BTK1and BANK1are downstream of preBCR or BCR is controlled by ZFP521and upregulation of BTK1and BANK1contributes to pre-B cell proliferation.

BANK1 is a modulator of the pre-B cell signaling pathway disrupted by IL-7R signaling that interacts with phospholipase gamma2 [40]. Overexpression of BANK1enhances BCR-induced calcium mobilization. Another lymphocytic associated kinase, LYN, associates with BANK1. LYN is activated with catalyst tyrosine phosphorylation of IP3R (Inositol 1,4,5-trisphosphate receptor).

BTK is a useful diagnostic marker for Hodgkin’s and B-cell non-Hodgkin’s lymphoma [41]. BTK-dependent pathways are involved in maintaining the malignant phenotype in B-cell lymphomas and leukemias [31, 42, 43, 44]. Anti-apoptosis signaling in various B-cell malignancies requires BTK-dependent signals from the B-cell antigen receptor. A distinct subset of human ALL is selectively sensitive to preBCR antagonists, such as those employed for ibrutinib therapy for B cell malignancy [31, 42, 43, 44] In contrast, several reports suggested that BTK acts as a tumor suppressor in the majority of human ALL cases [31, 41]. The BTK-dependent pathway is controlled in an expression dependent manner. Additionally, overexpressed BTK affects the survival or selection of B cells during the development of malignancies [45] and contributes to malignant transformation.

In humans, fusion of the Pax5exon 7 to ZNF521exon 4 has been observed in pre-B cell acute lymphocytic leukemia by genome-wide analysis of genetic alterations [46]. Importantly, this breakpoint is located near the conserved integration target sequence in human ZNF521, suggesting that the locus is active in pre-B cells as in Pax5, which is essential for pre-B cell development. Thus, we can conclude that aberrant release of the ZFP521gene control leads to pre-B cell lymphomagenesis through activation of pre-B cell-specific molecular signaling pathways. Moreover, c-Jun expression was observed in lymphoma tissues exhibiting ZFP521overexpression, suggesting that c-Jun is associated with lymphomagenesis [25].

MLV insertion into ZFP521gene was observed in the lymphomas with its insertion to Sat5, Hipk2,or Fiz1genes. These target tgenes may interact in the development of pre-B lymphoma. The dysregulation of this preBCR signal is responsible for pre-B cell lymphomagenesis [33]. ZFP521contributes to mouse and human pre-B cell lymphomagenesis (i.e., human B-cell lymphoblastic lymphoma). Pre-B cell proliferation depends on activation of preBCR signaling molecules including BANK1, which are upregulated by ZFP521.

ZFP521is involved in tumorigenesis in pre-B cell lymphoblastic lymphoma through upregulation of preBCR signaling molecules, interfering with the IL-7R signaling pathway. ZFP521also mediates the expression of Ccnd3, c-jun, and other cell cycle-related genes. Therefore, these data suggested that ZFP521might be a promising target for targeted molecular therapy for ALL or B-precursor lymphoma.


3. Conclusion

The early stage of B cell differentiation is characterized by immunoglobulin rearrangement. Rearrangement is controlled by both the enzyme RAG 1/2, and IL-7R and preBCR signaling pathways. These two pathways sometimes function cooperatively, sometimes antagonistically and seem to support the timing of immunoglobulin gene rearrangement.


4. Materials

4.1. SL/Kh strain

SL/Kh is an inbred mouse strain that shares the AKV1 pro-virus with the AKR strain, which is susceptible to T cell leukemia/lymphoma [3]. This strain has been developed over 30 years through brother-sister mating and acquired susceptibility to MLV-mediated pre-B lymphoma [47]. AKV was mapped as the endogenous ecotropic murine virus 11(Emv11) onto chromosome 7 [48, 49]. In this strain, the pro- to pre-B cells expand in the bone marrow in a polyclonal manner before monoclonal expansion [18]. Afterwards, more than one copy of the proviral genome is acquired during the development of lymphomagenesis. More than 90% of these mice spontaneously develop sIgM pro- or pre-B lymphomas, positive for preBCR, by 6 months of age. MLV genomes were integrated into Stat5, c-Myc, ZFP521, and other oncogenes in the lymphoma cell genome. Upregulation in expression of Stat5 and ZFP521 are not sufficient, as pre-B cell lymphomagenesis and a strain-dependent background are required [50, 51].



This work was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (Project No. 17013086;


Conflicts of interest

The authors have declared no conflict of interest.


Appendices and nomenclature

MLVmurine leukemia retrovirus
ZFP521zinc finger protein 521
Stat5asignal transducer and activator of transcription

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Tatsuaki Tsuruyama (November 5th 2018). Signaling Pathway for the Development of Pre-B Cells, Lymphocytes, Erman Salih Istifli and Hasan Basri İla, IntechOpen, DOI: 10.5772/intechopen.79733. Available from:

chapter statistics

837total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Understanding B Lymphocyte Development: A Long Way to Go

By Malavika Bhattacharya

Related Book

First chapter

In Vitro Cytotoxicity Screening as a Criterion for the Rational Selection of Tear Substitutes

By Olga I. Aleksandrova, Igor N. Okolov, Julia I. Khorolskaya, Natalia A. Mikhailova, Diana M. Darvish and Miralda I. Blinova

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us